Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Murphy: Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. (0.08 sec) 

Systemic CD4+ T cell phenotype and activation status in intermediate uveitis

- nih.gov - Free from Publisher
CC Murphy, L Duncan, JV Forrester, AD Dick - British Journal of Ophthalmology, 2004 - bjo.bmj.com
Methods: Peripheral blood lymphocytes of 18 patients with idiopathic
intermediate uveitis and 6 patients with presumed sarcoid intermediate uveitis
were evaluated for CD4 + T cell expression of CD69, CCR4, CCR5, CXCR3 and ...
Cited by 28 - Related articles - BL Direct - All 7 versions

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

- reumagalicia.com [PDF] 
H Al-Rayes, R Al-Swailem, M Al-Balawi, N Al- … - Rheumatology international, 2008 - Springer
Abstract In this open-label trial, ten male patients with active Behcet's
uveitis were enrolled. Initially, two inXix- imab infusions (5 mg/kg) were given
at weeks 0 and 2. The patients continued to receive conventional therapy on ...
Cited by 8 - Related articles - All 4 versions

[CITATION] Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy


H PJ - Clin. Exp. Rheum, 2003
Cited by 8 - Related articles

[CITATION] Backhouse OC. Does etanercept induce uveitis


R AR - Br. J. Ophthalmol, 2003
Cited by 8 - Related articles

[CITATION] Assessment and medical management of posterior uveitis and its complication


S Lightman, HMA Towler - Uveitis. London: BMJ Books, 1998
Cited by 9 - Related articles

[CITATION] Immunosuppressive treatment with mycophenolate mofetil (CellCept) in the therapy of …


M Zierhut, N Stubiger, W Aboalchamat, H … - Ophthalmologe, 2001 - Berlin; New York; Springer-Verlag, 1992-
Cited by 11 - Related articles

Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis


J Plskova, K Greiner, JV Forrester - American Journal of Ophthalmology, 2007 - Elsevier
The mean observation period was 11 months (range, one to 29 months). A positive
clinical response was observed in 83% of patients. Median visual acuity improved
from 0.54 to 0.2 (logarithm of the minimum angle of resolution units; P < ...
Cited by 15 - Related articles - All 12 versions

ORIGINAL ARTICLE, Interferon Alpha-2A Treatment for Serpiginous Choroiditis


G Sobaci, Z Bayraktar, A Bayer - Ocular Immunology and Inflammation, 2005 - informahealthcare.com
Purpose: To describe the management and long-term outcome of patients with
serpiginous choroiditis (SPC) treated with interferon (IFN) alpha-2a. Design:
Prospective, non-comparative case series. Participants: Five patients (8 ...
Cited by 15 - Related articles - All 5 versions

[CITATION] Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for …


GJ Jaffe, D Martin, D Callanan, A Pearson, B … - Ophthalmology, 2006
Cited by 14 - Related articles

Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppresive …


NA Rao - Ocular Immunology and Inflammation, 2006 - informahealthcare.com
Once the diagnosis of VKH is established, most clinicians with expertise in the
field of uveitis initially prescribe a high-dose corticosteroid, either orally
(1 to 1.5 mg/kg/day) or through a short course of intravenous delivery, ...
Cited by 14 - Related articles - BL Direct - All 5 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google